Results 141 to 150 of about 260,112 (235)

Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy development. [PDF]

Front Tuberc
Fuller NM, Davies NG, McHugh TD, Knight GM.   +3 more
europepmc   +1 more source

Principles of MDR-TB control

Journal of Microbiology, Immunology and Infection, 2015
openaire   +1 more source

Diagnostic assistance method for RR-TB/MDR-TB patients under treatment based on CNN-LSTM. [PDF]

Sci Rep
Li J, Wu W, Fang Z, Fu P, Huang H, Zhou Y, Yu L, Huang H, Wang T, Zhang Q.   +9 more
europepmc   +1 more source

The critical link between TB infection control process and clinical impact: need for efficacy data and MDR-TB specificity. [PDF]

J Clin Tuberc Other Mycobact Dis
Aphale P, Dokania S, Shekhar H.
europepmc   +1 more source

Global burden of MDR-TB and XDR-TB: trends, inequities, and future implications for public health planning. [PDF]

BMC Infect Dis
Tan EL, Qin Y, Yang J, Li XJ, Liu TQ, Yang GB, Li YJ, Zhang ZZ, Lu ZH, Wang JC, Zheng JX, Zhang SX.   +11 more
europepmc   +1 more source

Visual Recovery Following Linezolid Cessation in an MDR-TB Patient: Detailed Case Analysis. [PDF]

Case Rep Pulmonol
Wiyana YB, Marhana IA, Suhartono G, Haryono A.   +3 more
europepmc   +1 more source

Contributions of Community Advisory Board and Experience of Study Participants in TB/MDR-TB Clinical Trial Management in Addis Ababa, Ethiopia: A Qualitative Study. [PDF]

Dev World Bioeth
Seralegne Y, G/Medihin A, Hundito E, Adane H, Sintayehu B.   +4 more
europepmc   +1 more source

Wild-type MIC distribution and evaluation of epidemiological cut-offs of second-line TB-drugs in susceptible and MDR-TB clinical isolates from Chennai, India. [PDF]

Front Microbiol
Dusthackeer A, Balasubramanian M, Rajadas SE, Nirmal CR, Elango P, Thiruvengadam K, Saadhali SA, Shanmugam S.   +7 more
europepmc   +1 more source

Tuberculosis infection control in MDR-TB designated hospitals in Jiangsu Province, China. [PDF]

J Clin Tuberc Other Mycobact Dis
Song H, Li G, Xu Z, Wang F, Wang X, Dai B, Zhang X, Li J, Li Y, Zhu L.   +9 more
europepmc   +1 more source

Pyrazinamide susceptibility testing in <i>Mycobacterium tuberculosis</i>: impact of false-positive BD MGIT 960 results and added value of sequencing for accurate diagnosis in a low-MDR-TB-incidence context. [PDF]

Front Cell Infect Microbiol
Semenova T, Gonzalez G, Lechartier B, Sander P, von Garnier C, Schulthess B, Mazza-Stalder J, Greub G, Opota O.   +8 more
europepmc   +1 more source